These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

365 related articles for article (PubMed ID: 23446297)

  • 1. Targeted therapy for orbital and periocular basal cell carcinoma and squamous cell carcinoma.
    Yin VT; Pfeiffer ML; Esmaeli B
    Ophthalmic Plast Reconstr Surg; 2013; 29(2):87-92. PubMed ID: 23446297
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Vismodegib for periocular and orbital basal cell carcinoma.
    Gill HS; Moscato EE; Chang AL; Soon S; Silkiss RZ
    JAMA Ophthalmol; 2013 Dec; 131(12):1591-4. PubMed ID: 24136169
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy of Vismodegib (Erivedge) for Basal Cell Carcinoma Involving the Orbit and Periocular Area.
    Demirci H; Worden F; Nelson CC; Elner VM; Kahana A
    Ophthalmic Plast Reconstr Surg; 2015; 31(6):463-6. PubMed ID: 25675162
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy of Vismodegib for the Treatment of Orbital and Advanced Periocular Basal Cell Carcinoma.
    Eiger-Moscovich M; Reich E; Tauber G; Berliner O; Priel A; Ben Simon G; Elkader AA; Yassur I
    Am J Ophthalmol; 2019 Nov; 207():62-70. PubMed ID: 31077664
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of Food and Drug Administration Approval of Vismodegib on Prevalence of Orbital Exenteration as a Necessary Surgical Treatment for Locally Advanced Periocular Basal Cell Carcinoma.
    Sagiv O; Ding S; Ferrarotto R; Glisson B; Altan M; Johnson F; Elamin Y; Thakar SD; Nagarajan P; Esmaeli B
    Ophthalmic Plast Reconstr Surg; 2019; 35(4):350-353. PubMed ID: 30365473
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hedgehog Pathway Inhibition for Locally Advanced Periocular Basal Cell Carcinoma and Basal Cell Nevus Syndrome.
    Ozgur OK; Yin V; Chou E; Ball S; Kies M; William WN; Migden M; Thuro BA; Esmaeli B
    Am J Ophthalmol; 2015 Aug; 160(2):220-227.e2. PubMed ID: 25935097
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Indications and limitations of vismodegib for basal cell carcinoma.
    Yin VT; Sniegowski M; Esmaeli B
    JAMA Ophthalmol; 2014 Jul; 132(7):905-6. PubMed ID: 25010179
    [No Abstract]   [Full Text] [Related]  

  • 8. Indications and limitations of vismodegib for basal cell carcinoma--reply.
    Gill HS; Moscato EE; Silkiss RZ
    JAMA Ophthalmol; 2014 Jul; 132(7):906. PubMed ID: 25010181
    [No Abstract]   [Full Text] [Related]  

  • 9. Oral Hedgehog Pathway Inhibition as a Means for Ocular Salvage in Locally Advanced Intraorbital Basal Cell Carcinoma.
    Mathis J; Doerr T; Lin E; Ibrahim SF
    Dermatol Surg; 2019 Jan; 45(1):17-25. PubMed ID: 30586344
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Risk of cutaneous squamous cell carcinoma after treatment of basal cell carcinoma with vismodegib.
    Bhutani T; Abrouk M; Sima CS; Sadetsky N; Hou J; Caro I; Chren MM; Arron ST
    J Am Acad Dermatol; 2017 Oct; 77(4):713-718. PubMed ID: 28780365
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Vismodegib for the treatment of basal cell carcinoma: results and implications of the ERIVANCE BCC trial.
    Dessinioti C; Plaka M; Stratigos AJ
    Future Oncol; 2014 May; 10(6):927-36. PubMed ID: 24941979
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Increased Risk of Cutaneous Squamous Cell Carcinoma After Vismodegib Therapy for Basal Cell Carcinoma.
    Mohan SV; Chang J; Li S; Henry AS; Wood DJ; Chang AL
    JAMA Dermatol; 2016 May; 152(5):527-32. PubMed ID: 26914338
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacologic treatment options for advanced epithelial skin cancer.
    Soura E; Chasapi V; Stratigos AJ
    Expert Opin Pharmacother; 2015; 16(10):1479-93. PubMed ID: 26027692
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Expanded access study of patients with advanced basal cell carcinoma treated with the Hedgehog pathway inhibitor, vismodegib.
    Chang AL; Solomon JA; Hainsworth JD; Goldberg L; McKenna E; Day BM; Chen DM; Weiss GJ
    J Am Acad Dermatol; 2014 Jan; 70(1):60-9. PubMed ID: 24189279
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A comprehensive review of the role of the hedgehog pathway and vismodegib in the management of basal cell carcinoma.
    Erdem GU; Sendur MA; Ozdemir NY; Yazıcı O; Zengin N
    Curr Med Res Opin; 2015 Apr; 31(4):743-56. PubMed ID: 25690490
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Exploring vismodegib: A non-surgical breakthrough in the management of advanced periocular basal cell carcinoma.
    Lavasidis G; Tzamalis A; Tsinopoulos I; Ziakas N
    Cancer Treat Res Commun; 2024; 39():100796. PubMed ID: 38367414
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Not Available].
    Basset-Seguin N
    Ann Dermatol Venereol; 2018 Nov; 145 Suppl 5():VS36-VS41. PubMed ID: 30477683
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Vismodegib for Preservation of Visual Function in Patients with Advanced Periocular Basal Cell Carcinoma: The VISORB Trial.
    Kahana A; Unsworth SP; Andrews CA; Chan MP; Bresler SC; Bichakjian CK; Durham AB; Demirci H; Elner VM; Nelson CC; Kim DS; Joseph SS; Swiecicki PL; Worden FP
    Oncologist; 2021 Jul; 26(7):e1240-e1249. PubMed ID: 33988881
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Development of squamous cell carcinoma into basal cell carcinoma under treatment with Vismodegib.
    Saintes C; Saint-Jean M; Brocard A; Peuvrel L; Renaut JJ; Khammari A; Quéreux G; Dréno B
    J Eur Acad Dermatol Venereol; 2015 May; 29(5):1006-9. PubMed ID: 24980899
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hedgehog Pathway Inhibition.
    Sekulic A; Von Hoff D
    Cell; 2016 Feb; 164(5):831. PubMed ID: 26919418
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.